Perrigo Company plc Other Comprehensive Income (Loss), Net of Tax
Perrigo Company plc (PRGO) reported Other Comprehensive Income (Loss), Net of Tax of $72.20 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2018-05-08
- Perrigo Company plc other comprehensive income (loss), net of tax for the quarter ending 2018-03-31 was $72.20M, a 30.09% increase year-over-year.
- Perrigo Company plc other comprehensive income (loss), net of tax for the quarter ending 2017-09-30 was $60.70M, a 49.14% increase year-over-year.
- Perrigo Company plc other comprehensive income (loss), net of tax for the quarter ending 2017-07-01 was $156.80M.
- Perrigo Company plc other comprehensive income (loss), net of tax for the quarter ending 2017-04-01 was $55.50M, a 63.65% decline year-over-year.
- Perrigo Company plc other comprehensive income (loss), net of tax for fiscal 2016 was -$66.50M.
- Perrigo Company plc other comprehensive income (loss), net of tax for fiscal 2015 was -$36.10M, a 157.67% decline from fiscal 2014.
- Perrigo Company plc other comprehensive income (loss), net of tax for fiscal 2014 was $62.60M, a 66.49% increase from fiscal 2013.
- Perrigo Company plc other comprehensive income (loss), net of tax for fiscal 2013 was $37.60M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 6 month as first filed | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 9 month as first filed | Other Comprehensive Income (Loss), Net of Tax 12 month | Other Comprehensive Income (Loss), Net of Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-03-31 | $72.20M 10-Q · filed 2018-05-08 | |||||||
| 2017-09-30 | $60.70M 10-Q · filed 2017-11-09 | $217.50M derived: sum of 2 quarters · filed 2017-11-09 | $273.00M 10-Q · filed 2017-11-09 | $119.70M derived: sum of 4 quarters · filed 2018-05-08 | ||||
| 2017-07-01 | $156.80M 10-Q · filed 2017-08-10 | $212.30M 10-Q · filed 2017-08-10 | $59.00M derived: sum of 3 quarters · filed 2018-05-08 | $99.70M derived: sum of 4 quarters · filed 2018-05-08 | ||||
| 2017-04-01 | $55.50M 10-Q · filed 2018-05-08 | -$97.80M derived: sum of 2 quarters · filed 2018-05-08 | -$57.10M derived: sum of 3 quarters · filed 2018-05-08 | -$163.90M derived: sum of 4 quarters · filed 2018-05-08 | ||||
| 2016-12-31 | -$153.30M derived: 10-K 12 month − 10-Q 9 month · filed 2017-05-22 | -$112.60M derived: sum of 2 quarters · filed 2017-11-09 | -$219.40M derived: sum of 3 quarters · filed 2017-11-09 | -$66.50M 10-K · filed 2017-05-22 | ||||
| 2016-10-01 | $40.70M 10-Q · filed 2017-11-09 | $40.20M 10-Q · filed 2016-11-10 | -$66.10M derived: sum of 2 quarters · filed 2017-11-09 | $86.80M 10-Q · filed 2017-11-09 | $87.00M 10-Q · filed 2016-11-10 | $5.10M derived: sum of 4 quarters · filed 2017-11-09 | ||
| 2016-07-02 | -$106.80M 10-Q · filed 2017-08-10 | -$105.40M 10-Q · filed 2016-08-10 | $46.00M 10-Q · filed 2017-08-10 | $46.80M 10-Q · filed 2016-08-10 | -$35.60M derived: sum of 3 quarters · filed 2017-08-10 | -$72.90M derived: sum of 4 quarters · filed 2017-08-10 | ||
| 2016-04-02 | $152.70M 10-Q · filed 2017-05-30 | $152.20M 10-Q · filed 2016-05-16 | $71.20M derived: sum of 2 quarters · filed 2017-05-30 | $33.90M derived: sum of 3 quarters · filed 2017-05-30 | $156.30M derived: sum of 4 quarters · filed 2017-05-30 | |||
| 2015-12-31 | -$81.50M derived: 10-K 6 month − 10-Q/A 3 month · filed 2017-05-22 | -$118.80M 10-K · filed 2017-05-22 | -$117.90M 10-KT · filed 2016-02-25 | $3.60M derived: sum of 3 quarters · filed 2017-05-23 | -$22.70M derived: sum of 4 quarters · filed 2017-05-23 | |||
| 2015-09-26 | -$37.30M 10-Q/A · filed 2017-05-23 | -$37.20M 10-Q · filed 2015-11-02 | $85.10M derived: sum of 2 quarters · filed 2017-05-23 | $58.80M 10-Q/A · filed 2017-05-23 | $57.80M 10-Q · filed 2016-11-10 | -$8.10M derived: sum of 4 quarters · filed 2017-05-23 | ||
| 2015-06-27 | $122.40M 10-Q/A · filed 2017-05-22 | $121.40M 10-Q · filed 2016-08-10 | $96.10M 10-Q/A · filed 2017-05-22 | $95.00M 10-Q · filed 2016-08-10 | $29.20M derived: sum of 3 quarters · filed 2017-05-22 | -$36.10M 10-K · filed 2017-05-22 | -$37.20M 10-K · filed 2015-08-13 | |
| 2015-03-28 | -$26.30M 10-Q/A · filed 2017-05-22 | -$93.20M derived: sum of 2 quarters · filed 2017-05-22 | -$158.60M 10-Q · filed 2015-04-29 | -$149.20M derived: sum of 4 quarters · filed 2017-05-22 | ||||
| 2014-12-27 | -$66.90M 10-Q · filed 2015-02-05 | -$132.20M 10-Q · filed 2015-02-05 | -$122.90M derived: sum of 3 quarters · filed 2017-05-22 | -$107.20M derived: sum of 4 quarters · filed 2017-05-22 | ||||
| 2014-09-27 | -$65.30M 10-Q · filed 2015-11-02 | -$56.00M derived: sum of 2 quarters · filed 2017-05-22 | -$40.30M derived: sum of 3 quarters · filed 2017-05-22 | -$30.00M derived: sum of 4 quarters · filed 2017-05-22 | ||||
| 2014-06-28 | $9.30M derived: 10-K 12 month − 10-Q 9 month · filed 2017-05-22 | $25.00M derived: sum of 2 quarters · filed 2017-05-22 | $35.30M derived: sum of 3 quarters · filed 2017-05-22 | $62.60M 10-K · filed 2017-05-22 | ||||
| 2014-03-29 | $15.70M 10-Q · filed 2015-04-29 | $26.00M derived: sum of 2 quarters · filed 2015-04-29 | $53.30M 10-Q · filed 2015-04-29 | |||||
| 2013-12-28 | $10.30M 10-Q · filed 2015-02-05 | $37.60M 10-Q · filed 2015-02-05 | ||||||
| 2013-09-28 | $27.30M 8-K · filed 2014-11-20 | -$16.51M 10-Q · filed 2013-11-04 | ||||||
| 2013-06-29 | $37.60M 10-KT · filed 2016-02-25 | |||||||
| 2012-09-29 | $37.60M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |